GlobeNewswire

GMAC Launches 'Study in China' Initiative in Partnership with 11 Leading Business Schools in China

Dela

BEIJING and HONG KONG, June 22, 2018 (GLOBE NEWSWIRE) -- On June 22, the Graduate Management Admission Council (GMAC) joins hands with 11 leading business schools in China to launch the "Study in China" initiative. This partnership marks the opening of an interactive platform for international students across 20 Belt and Road (B&R) regions to explore opportunities in China and to pursue higher education in business-related fields. The "Study in China" initiative aims to meet rapidly growing international student demand and to champion China as a world-class study destination and emerging global hub for business education.

The "Study in China" online portal (www.studyinchinamba.com) officially launched today allows students to discover more about studying and living in China. The newly designed English-language website connects prospective students with partner business schools and offers access to an abundance of information to help find the perfect fit for their China education experience. GMAC's gateway guides international applicants from these Belt and Road regions in Asia, the Middle East, Africa, and Europe through the necessary steps to begin a new learning chapter in one of the most dynamic economies in the world. It offers in-depth information and insider advice on the schools and programs available, including international program structure, syllabus overview, admission requirements, application times, campus facilities, scholarships and financial aid. Students can also opt-in to conveniently contact the schools for further detail via GMAC's one-stop portal.

To offer a glimpse into the great opportunities available, GMAC is organizing a "Study in China" contest from June 22 to August 31. Participants submit short essays about why they want to study in China to win a round-trip to China. Three selected winners will be awarded return economy flights and campus accommodation to visit preferred business schools and enjoy a first-hand experience of the school and campus life.

The new initiative partners with China's most prestigious business schools located in Beijing, Shanghai, and Hong Kong. The top-ranked institutions include Antai College of Economics and Management, Shanghai Jiao Tong University; China Europe International Business School; CUHK Business School, The Chinese University of Hong Kong; School of Management, Fudan University; HKUST Business School, The Hong Kong University of Science and Technology; Guanghua School of Management, Peking University; Business School, Renmin University of China; School of Economics and Management, Tsinghua University; BiMBA Business School of the National School of Development, Peking University; Cheung Kong Graduate School of Business; and HKBU School of Business, Hong Kong Baptist University.

Mr. Sangeet Chowfla, the President and CEO of GMAC, announced GMAC's pride in creating more opportunities for prospective students to access business education. He believes "This will effectively connect international talent with the right opportunities to excel at China's leading business schools and programs, while offering students all around support during the study abroad period." Mr. Chowfla emphasized GMAC's observations over the past few years, as China holds the potential "to become one of the most popular study destinations." This "Study in China" initiative, according to Chowfla, intends to further raise the profile of business schools in China and showcase the value of business education to international candidates.

Professor Lu Xiongwen, Dean of the School of Management at Fudan University, expressed his congratulations on the launch of the new initiative and extended a warm welcome to prospective students looking to come study in China. He quoted an old Chinese proverb that says, "Practice goes deeper than theoretic knowledge," indicating that these programs would open new doors of understanding. "I believe this learning journey will present you a broad picture of China's economic trends at present and future, the uniqueness of Chinese business models as well as different features of the Chinese market and global market," said Prof. Lu. "You will also enjoy the opportunity of learning about and appreciating China's profound culture immersed in thousands of years of history."

Professor Kar Yan Tam, Dean of the HKUST Business School, also commented on the initiative, saying that "China will remain the world's major growth engine in the years ahead, with reforms to allow its economy to unleash new potential and the Belt and Road initiative to bring a sustained momentum to the region." He also highlighted that "Students should not only receive the best international business education to develop a global perspective, but also look for opportunities to experience the vitality of China. Hong Kong is a dynamic and international city where students can enjoy access to a unique fusion of East and West. The city also stays at the forefront of business education and offers different enriching and diverse learning experiences to prepare students for a flourishing career in China and beyond."

The "Study in China" initiative exemplifies GMAC's consistent efforts in promoting business education around the world. This network acts as a bridge within the B&R community to empower students' professional journeys as future business leaders and entrepreneurs in China and abroad.

About GMAC:  The Graduate Management Admission Council (GMAC) is a global, non-profit association of leading graduate business schools. Founded in 1953, we are committed to creating solutions for business schools and candidates to better discover, evaluate and connect with each other. We work on behalf of the schools and the graduate management education community, as well as guide candidates on their journey to higher education, to ensure that no talent goes undiscovered.

GMAC provides world-class research, professional development opportunities and assessments for the industry, designed to advance the art and science of admissions. Owned and administered by GMAC, the Graduate Management Admission Test® (GMAT®) is the most widely used graduate business school assessment, recognized by more than 7,000 programs worldwide. Other GMAC assessments include the NMAT by GMAC(TM) exam, for entrance into graduate management programs in India and South Africa, and the Executive Assessment, specifically designed for Executive programs around the world. Our flagship portal for graduate management education resources and information, www.mba.com, receives 14 million visits a year and features the School Search matching tool and Graduate Management Admission Search Service (GMASS), matching candidates and business schools.  

GMAC is based in the United States with offices in the United Kingdom, India, and Hong Kong. To learn more about our work, please visit www.gmac.com.

Media contact: 
Yolanda Kwok, Regional Director, Greater China, GMAC
ykwok@gmac.com

Susanna Lee, Associate Director, Marketing, Greater China, GMAC
slee@gmac.com

 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Graduate Management Admission Council via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum